The Relationship Between Total Sialic Acid and Superoxide Dismutase and the Diagnosis and Prognosis of Lipoid Pneumonia

Superoxide Dismutase Clinical Trial

Official title:

A Study to Explore the Correlation Between Total Sialic Acid Combined With Superoxide Dismutase and the Diagnosis and Prognosis of Lipoid Pneumonia

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT06430008
• Other study ID #: 2024-KY-144
• Status: Enrolling by invitation
• Start date: May 1, 2024
• Est. completion date: December 31, 2024

Study information

• Verified date: May 2024
• Source: China-Japan Friendship Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this observational study is to explore the correlation between total sialic acid combined with superoxide dismutase and the diagnosis and prognosis of lipid pneumonia in the patient with lipid pneumonia, cough, bacterial and fungal pneumonia, cryptogenic organizing pneumonia, pulmonary alveolar proteinosis, lung mucinous adenocarcinoma and pulmonary edema. The main question it aims to answer is:

Whether superoxide dismutase (SOD) and total sialic acid (TSA) could be used as diagnostic markers to distinguish lipid pneumonia from patient with cough, and bacterial and fungal pneumonia, cryptogenic organizing pneumonia, pulmonary alveolar proteinosis, lung mucinous adenocarcinoma and pulmonary edema, whether SOD and TSA be associated with the prognosis of patients with lipid pneumonia?

Participants will answer online survey questions about their symptoms, changes in oxygen status, and changes in the most recent CT image of the lung for up to 10 years after treatment. We will count participants' baseline data including: gender, age, smoking history, comorbidities, lung function, imaging findings, hormone use or not, ICU treatment, death or not, the type of cause of lipid pneumonia, how it is diagnosed, and their baseline SOD and TSA.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 160
• Est. completion date: December 31, 2024
• Est. primary completion date: October 1, 2024
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age= 18 years old;

2. The diagnosis of lipoid pneumonia must be supported by lung biopsy pathological support or positive oil red O or Sudan staining in bronchoalveolar lavage fluid;

3. Patients with bacterial and fungal pneumonia must be supported by etiological evidence;

4. Patients with cryptogenic organizing pneumonia and pulmonary alveolar proteinosis must be supported by lung biopsy pathology;

5. Patients with lung mucinous adenocarcinoma must be supported by lung tissue biopsy;

6. Lung imaging of patients with pulmonary edema must show paving stone signs;

Exclusion Criteria:

1. Age< 18 years old;

2. The patient only has a history of lipid inhalation and no pathology or positive lipoid staining;

3. Co-infection with the corona virus disease 2019 at the onset of illness;

4. Pregnant

Related Conditions & MeSH terms

• Pneumonia
• Superoxide Dismutase

Locations

Country	Name	City	State
China	China-Japan Friendship Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Hu Yinan

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	superoxide dismutase		At the time of admission
Secondary	sialic acid		At the time of admission
Secondary	death or not		Within 10 years after discharge
Secondary	neutrophil-to-lymphocyte ratio		At the time of admission